Dianthus Therapeutics (DNTH) vs Ionis Pharmaceuticals (IONS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dianthus Therapeutics (DNTH) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 144.6% versus a loss of 35.9%. Over five years, IONS leads with a +25.8% price change compared with -21.2% for DNTH. Ionis Pharmaceuticals is the larger company by market cap ($7.34 billion vs $4.75 billion), about 1.5 times the size.
Ionis Pharmaceuticals converts more of its revenue into profit, with a net margin of -40.4% versus -7973.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNTH | IONS |
|---|---|---|
| Share price | $84.88 | $44.16 |
| Market cap | $4.75B | $7.34B |
| 1-day change | -0.61% | +0.36% |
| YTD return | +105.97% | -44.18% |
| 1-year return | +144.61% | -35.94% |
| 5-year return | -21.17% | +25.81% |
| EPS (TTM) | $-4.21 | $-3.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | $943.71M |
| Revenue growth (YoY) | -67.35% | +33.83% |
| Net income (latest FY) | $-162.34M | $-381.39M |
| Gross margin | — | 98.31% |
| Operating margin | -8739.34% | -40.45% |
| Net margin | -7973.33% | -40.41% |
| 52-week high | $117.88 | $86.74 |
| 52-week low | $32.22 | $42.63 |
| Distance from 52-week high | -27.99% | -49.09% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +65.88% | +89.40% |
| Average volume | 825.33K | 3.79M |
| Shares outstanding | 55.93M | 166.18M |
| Employees | 92 | 1,480 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DNTH has outperformed IONS by 180.6 percentage points over the past year.
- Ionis Pharmaceuticals is more profitable, keeping -40.4 cents of every revenue dollar as net income versus -7973.3 cents for Dianthus Therapeutics.
- Ionis Pharmaceuticals grew revenue faster in its latest fiscal year (+33.83% vs -67.35%).
About Dianthus Therapeutics
DNTH stock →Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
Healthcare · Biotechnology · 92 employees
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Healthcare · Biotechnology · 1,480 employees
DNTH vs IONS FAQ
Which is bigger, Dianthus Therapeutics or Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) is larger, with a market capitalization of $7.34B compared with $4.75B for Dianthus Therapeutics (DNTH).
Which stock has performed better over the past year, DNTH or IONS?
DNTH returned +144.61% over the past 12 months, compared with -35.94% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Dianthus Therapeutics and Ionis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.